Quantcast

Latest Coagulation system Stories

2014-06-16 04:21:39

IMPACT Dx(TM) Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 /PRNewswire/ -- Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., was notified today by Sequenom, Inc. that it received premarket clearance from the U.S. Food and Drug Administration (FDA) for the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx(TM) System. The IMPACT Dx(TM) Factor V Leiden and Factor II...

2014-06-11 08:32:01

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coagulation Diagnostic Testing Marketshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/coagulation_diagnostic_testing_markets_1.html Coagulation testing, which encompasses both laboratory and point of care (POC) testing, will continue to be one of the most important segments of the in vitro diagnostics market for the foreseeable future. Many of the new models of laboratory...

2014-06-10 23:02:32

Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/hemophilia-treatment-market.html. Albany, New York (PRWEB) June 10, 2014 Hemophilia is a group of hereditary genetic disorders that affects the body’s ability to control blood coagulation. The bleeding can be internal or external,...

2014-05-22 08:28:45

Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXI(Rx) undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-05-11 20:21:16

Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups. These...

2014-05-07 23:14:26

Conquer Low Platelets designed by Louis Cruz is a new program that provides people with natural remedies, techniques, tips, and detailed instructions on how to increase platelets easily. An overview on the website Vinaf.com shows if the program is good for people to use. Tampa, FL (PRWEB) May 07, 2014 Conquer Low Platelets is a new program developed by Louis Cruz, a medical consultant, who has over 11 years of experience in the health care industry. The program provides people with...

2014-05-02 08:25:41

KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of previously treated children (up to age 11 years) with severe hemophilia A. The study site for this first enrollment is Malaysia. A minimum of 25 previously treated...

2014-04-29 08:34:35

Recently Released ACC/AHA Practice Guidelines Reinforce Unmet Need MENLO PARK, Calif., April 29, 2014 /PRNewswire/ -- Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin. Tecarfarin is positioned to be the only oral anticoagulant (OAC) therapy for patients with prosthetic heart valves (PHV) specifically identified in the label. In addition, the...

2014-04-28 16:29:07

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Antithrombotic Drugs: World Market 2013-2023 http://www.reportbuyer.com/pharma_healthcare/therapeutic/antithrombotic_drugs_world_market.html Report DetailsAntithrombotic agents - discover technological and commercial prospectsWhat does the future hold for treating conditions associated with thrombosis? Visiongain's updated report gives you forecasted revenues to 2023, explaining R&D...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.